SOURCE-LINKED STUDY SUMMARY
Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.
Full paper summarizedQuality not appraised
- What was studied
- A mechanistic secondary analysis of SUMMIT examined blood pressure, estimated blood volume, inflammation and kidney markers.
- Who / model studied
- Adults with obesity and heart failure with preserved ejection fraction: 364 assigned tirzepatide and 367 placebo.
- Studied dose & schedule
- Subcutaneous tirzepatide started at 2.5 mg weekly, increasing by 2.5 mg every 4 weeks as tolerated to 15.0 mg. Outcomes assessed at 52 weeks.
- What the study found
- Versus placebo, systolic pressure fell 5 mmHg, estimated blood volume fell 0.58 L and CRP fell 37.2%. Cystatin-C-based kidney filtration estimates improved; the urine albumin–creatinine difference was not statistically significant at 52 weeks.
- Limitations & context
- Blood volume was calculated using a weight-based formula, not directly measured. Volume and mechanistic correlation analyses were exploratory. Findings apply to obesity-related heart failure, not healthy users.
Read summary source ↗ · Prepared 9/29/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s41591-024-03374-z